Leuprorelin Sandoz (Leuprorelin)

Leuprorelin is a synthetic GnRH analog that continuously stimulates pituitary GnRH receptors. This leads to an initial rise followed by down‑regulation of LH and FSH secretion, resulting in markedly reduced testosterone and estrogen levels, which underpins its therapeutic effect.

The dosage of Leuprorelin is individualized by the prescribing clinician based on the specific indication, patient characteristics, and treatment goals. Exact dosing regimens are determined by the treating physician and should follow the product’s prescribing information.

Leuprorelin is not recommended for use during pregnancy or while breastfeeding because its safety profile in these populations has not been established. Women of child‑bearing potential should use effective contraception during treatment.

To order Leuprorelin Sandoz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Leuprorelin belongs to the same class of GnRH agonists as leuprolide and goserelin. All share a similar mechanism of suppressing LH and FSH, but differences may exist in formulation, dosing frequency, and pharmacokinetic profiles. Choice of agent often depends on clinical preference, convenience of administration, and specific regulatory approvals.

Leuprorelin should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. The product should remain in its original packaging until use to maintain stability and sterility.

Leuprorelin is administered by subcutaneous injection, typically using a pre‑filled syringe or vial as directed by the healthcare professional. Injection sites are rotated to minimize local irritation, and administration is performed under aseptic conditions.

Serious risks include cardiovascular events such as myocardial infarction, severe allergic reactions (anaphylaxis), significant loss of bone mineral density leading to fractures, and hepatic function abnormalities. Patients should be monitored regularly for these potential complications.

Leuprorelin is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. It should also be avoided in pregnant or breastfeeding women, and used with caution in patients with severe cardiovascular disease, uncontrolled diabetes, or existing osteoporosis.